{"id":"ceb-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3693887","moleculeType":"Small molecule","molecularWeight":"478.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CEB-01 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"CEB-01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:07.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04619056","phase":"PHASE1","title":"First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"CEBIOTEX","startDate":"2020-06-03","conditions":"Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma","enrollment":21},{"nctId":"NCT06986811","phase":"PHASE2","title":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","status":"RECRUITING","sponsor":"CEBIOTEX","startDate":"2025-05-06","conditions":"Locally Resectable Paediatric Tumours","enrollment":60},{"nctId":"NCT06538857","phase":"PHASE2","title":"CEB-01 in Locally Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"CEBIOTEX","startDate":"2024-08-20","conditions":"Pancreatic Carcinoma","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CEB-01","genericName":"CEB-01","companyName":"CEBIOTEX","companyId":"cebiotex","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CEB-01 is being studied in clinical trials for the treatment of pancreatic carcinoma, locally resectable paediatric tumours, locally advanced soft tissue sarcoma, and recurrent soft tissue sarcoma. The CEB-01 membrane loaded with SN-38 is being tested in combination with standard surgery in these trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}